Assenagon Asset Management
IMVT icon

Assenagon Asset Management’s Immunovant IMVT Stock Holding History

Assenagon Asset Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$639K Sell
16,577
-188,642
-92% -$5.75M ﹤0.01% 1040
2026
Q1 		$5.1M Hold
205,219
– – 0.01% 579
2025
Q4 		$5.22M Hold
205,219
– – 0.01% 630
2025
Q3 		$3.31M Buy
+205,219
New +$3.32M ﹤0.01% 701
2024
Q3 		– Sell
-311,525
Closed -$8.22M – 1408
2024
Q2 		$8.22M Buy
311,525
+207,003
+198% +$5.89M 0.02% 484
2024
Q1 		$3.38M Sell
104,522
-16,746
-14% -$611K 0.01% 709
2023
Q4 		$5.11M Buy
+121,268
New +$4.46M 0.01% 632

Other funds holding IMVT

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
TC
Trust Company Manhattan, Kansas $1.11B AUM 13.1% 1-Year Est. Return

Assenagon Asset Management's IMVT Position: Q2 2026 in Review

Assenagon Asset Management reduced its Immunovant (IMVT) stake by 92% in Q2 2026, selling an estimated $5.75M and leaving 16,577 shares worth $639K. The position accounts for ﹤0.01% of the portfolio, ranked #1040.

Assenagon Asset Management first reported a position in IMVT in Q4 2023 and has held it in 7 quarters since. The position peaked at $8.22M in Q2 2024. 9 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Assenagon Asset Management held 16,577 shares of Immunovant worth $639K as of Q2 2026.
  • Assenagon Asset Management sold 188,642 Immunovant shares in Q2 2026, an estimated $5.75M.
  • Immunovant made up ﹤0.01% of Assenagon Asset Management's portfolio in Q2 2026, its #1040 holding.
  • Assenagon Asset Management first reported a position in Immunovant in Q4 2023 and has held it in 7 quarters since.
  • Assenagon Asset Management's Immunovant position peaked at $8.22M in Q2 2024.
  • 9 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.